WO2013008681A1 - 線維症予防又は治療用医薬組成物 - Google Patents
線維症予防又は治療用医薬組成物 Download PDFInfo
- Publication number
- WO2013008681A1 WO2013008681A1 PCT/JP2012/066971 JP2012066971W WO2013008681A1 WO 2013008681 A1 WO2013008681 A1 WO 2013008681A1 JP 2012066971 W JP2012066971 W JP 2012066971W WO 2013008681 A1 WO2013008681 A1 WO 2013008681A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stc1
- fibrosis
- pharmaceutical composition
- preventing
- pulmonary fibrosis
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a pharmaceutical composition for preventing fibrosis, particularly pulmonary fibrosis, suppressing progression and / or treating it.
- Interstitial pneumonia is an intractable disease characterized by inflammation of the lung stroma (parts other than the alveoli). It is known that 50% of patients with interstitial pneumonia shift to idiopathic pulmonary fibrosis and become severe. Pulmonary fibrosis is a disease in which the lungs become hard and shrink and gas exchange is inadequate. As this symptom progresses, it eventually falls into dyspnea and leads to death. Idiopathic pulmonary fibrosis patients are said to be 15,000 in Japan and 50,000 in the United States.
- STC1 Staniocalcin 1
- STC1 is a dimeric glycoprotein hormone discovered from fish gills and distributed to mammals. STC1 is known to have various physiological activities such as mitochondrial oxidative phosphorylation, nerve cell and myocardial protection, and bone metabolism promotion, in addition to phosphorus and calcium metabolism.
- STC1 reduces the membrane potential of intracellular mitochondria through induction of uncoupling protein 2 (UCP2) (Non-Patent Documents 1 to 3).
- UCP2 uncoupling protein 2
- ROS intracellular peroxide
- STC1 induces uncoupling metabolism (which leads to increased lactate amount, increased oxygen consumption, and increased lipid metabolism), which is neither anaerobic metabolism nor aerobic metabolism.
- Uncoupled metabolism is thought to be advantageous for survival in a disordered environment because it can consume more energy during starvation (or in a disordered environment) and also reduces peroxidative stress (Non-Patent Document 3, 4).
- Non-Patent Document 5 and Patent Document 1 disclose that when a nephritis model mouse is prepared by administering a substance that induces nephritis (Anti-GBM Ab), fibrosis occurs in the kidney tissue of the mouse. Then, when nephritis-inducing substances were administered to wild type (WT) mice and STC1 high-expressing mice, it became clear that the kidneys of STC1 high-expressing mice had less fibrosis of kidney tissue than WT mice. It is described.
- STC1 has been proposed for use as a pharmaceutical composition based on various physiological activities such as adipocyte differentiation or maturation inhibitory activity, bone formation promotion, and neuroprotective action (Patent Documents 2 to 5).
- Patent Documents 2 to 5 there is no known prior art that shows potential as a medicine for pulmonary fibrosis.
- An object of the present invention is to provide a pharmaceutical composition useful as a preventive and therapeutic agent for fibrosis, particularly pulmonary fibrosis.
- the present inventors studied STC1 with the expectation that STC1 may prolong the survival of lung cells under hypoxia or activate the function because it reduces ROS stress. And it discovered that pulmonary fibrosis was suppressed remarkably in the experimental pulmonary fibrosis model mouse which administered STC1 intratracheally, and completed this invention.
- a pharmaceutical composition for preventing, treating and / or suppressing progression of fibrosis comprising STC1 as an active ingredient; [2] The pharmaceutical composition according to the above [1], wherein the fibrosis is pulmonary fibrosis.
- the pharmaceutical composition of the present invention can prevent, suppress progression and / or treat fibrosis, particularly pulmonary fibrosis.
- STC1 is advantageous.
- Predonine, cyclosporin-A, FK506, and the like strongly suppress immunity and thus cause infectivity.
- STC1 is reported not to cause suppression of the immune system (Transgenic Res (2010) 19: 1017? 1039), and is therefore expected to have no infectious problem.
- N-acetylcystein (NAC) has the disadvantage that it cannot be administered intravenously, and STC1 is considered advantageous in comparison with NAC.
- FIG. 1 is a diagram showing a stained image of lung tissue of an individual in the STC1 administration group.
- Panel A represents an image stained with hematoxylin and eosin (HE), and panel B represents an image stained with elastica masson (EM) (the same applies to FIGS. 2 to 5).
- FIG. 2 is a diagram showing a stained image of lung tissue of another individual in the STC1 administration group.
- FIG. 3 is a diagram showing a stained image of lung tissue of an individual in a bleomycin (Bleo) administration group.
- FIG. 4 is a diagram showing a stained image of lung tissue of another individual in the bleomycin (Bleo) administration group.
- FIG. 5 is a diagram showing a stained image of lung tissue of an individual in an N-acetylcysteine (NAC) administration group.
- FIG. 6 shows a stained image of normal lung tissue.
- Panel A shows an HE-stained image
- Panel B shows an EM-stained image
- Panel C shows an 8-hydroxydeoxyguanuosine (8OHDG) -stained image.
- FIG. 7 is a diagram showing stained images of lung tissue of bleomycin (panels A, D, G), STC1 (panels B, E, H), and NAC (panels C, F, I) administration group.
- Panels A to C represent HE-stained images
- panels D to F represent EM-stained images
- panels G to I represent 8OHDG-stained images.
- the pharmaceutical composition for preventing or treating fibrosis of the present invention is characterized by containing STC1 as an active ingredient.
- the STC1 used in the present invention is based on a natural STC1 molecule obtained from an animal cell or tissue or the like, a recombinant STC1 having the same amino acid sequence as the natural STC1, or an STC1 gene modified by genetic engineering technology.
- any of functional equivalents such as an active fragment of STC1 may be used. Accordingly, the term “stanniocalcin 1” (STC1) in the context of the present invention is used to encompass these various STC1s unless otherwise indicated.
- the STC1 used in the present invention is preferably one having a human-derived amino acid sequence or one modified based on a human-derived amino acid sequence without impairing the function.
- the amino acid sequence and base sequence of human STC1 are known and are registered in the bank under the registration numbers NP # 003146.1 and NM # 003155.2.
- the amino acid sequences and base sequences of STC1 derived from many animals are known. All of these are, for example, 94% fish (coho salmon) and birds (chicken) compared to human STC1. ) 95% and 100% of various mammals are known to have high homology (Table 1).
- STC1 usable in the present invention has a homology of 80% or more, preferably 90% or more, and most preferably 94% or more with respect to the amino acid sequence of human STC1.
- rSTC1 natural or recombinant STC1 having an amino acid sequence that is 100% identical to a human STC1 sequence (for example, a human STC1 sequence derived from 293 cells).
- rSTC1 natural or recombinant STC1 having an amino acid sequence that is 100% identical to a human STC1 sequence (for example, a human STC1 sequence derived from 293 cells).
- rSTC1 natural or recombinant STC1 having an amino acid sequence that is 100% identical to a human STC1 sequence (for example, a human STC1 sequence derived from 293 cells).
- one or more of these STC1s can be appropriately selected and used.
- the pharmaceutical composition of the present invention comprises STC1 as the only essential component, but may optionally include a component that is considered to have an effective action for improving fibrosis.
- a component that is considered to have an effective action for improving fibrosis for example, steroid preparations such as predonin, reducing agents such as N-acetylcysteine, antifibrotic agents such as pirfenidone, immunosuppressive drugs such as cyclosporin A and FK506, components of glucose infusion, Ringer's infusion, etc.
- immunosuppressive drugs such as cyclosporin A and FK506, components of glucose infusion, Ringer's infusion, etc.
- the pharmaceutical composition of the present invention can be used in combination with these drugs and the like.
- “amelioration” of fibrosis is used in the meaning including prevention and treatment (including remission and cure).
- the pharmaceutical composition of the present invention can be formulated and administered using various ingredients known in the pharmaceutical or food industry.
- the administration route may be any known oral or parenteral route.
- any route such as oral, transdermal, injection, enteral and rectal can be selected.
- Preferred routes of administration include tracheal administration and, as in the case of hormone preparations, oral or injection or infusion.
- the form of the pharmaceutical composition includes an injection composition, an infusion composition, a suppository, a nasal agent, a sublingual agent, a percutaneous absorption agent and the like.
- the pharmaceutical composition of the present invention includes, as additives, excipients, disintegrants, lubricants, binders, surfactants, fluidity promoters, colorants, stabilizers, fragrances and the like known in the pharmaceutical industry.
- a pharmaceutical composition having a desired dosage form can be obtained by appropriately adding.
- isotonic agents such as sodium chloride, buffers such as phosphate or citrate, pH adjusters, sugars such as glucose, stabilizers, solubilizers, etc.
- Any component used for injections can be used.
- the pharmaceutical composition of the present invention may be dissolved in an aqueous carrier such as physiological saline and administered as a sterilized liquid, or a powder preparation for injection is prepared and dissolved in an aqueous carrier.
- the prepared solution may be prepared and administered at the time of use.
- oral preparations such as powders, granules, tablets, and capsules can be formulated by conventional methods using sugars such as starch, carboxymethylcellulose, corn starch, and inorganic salts.
- sugars such as starch, carboxymethylcellulose, corn starch, and inorganic salts.
- binders, disintegrants, surfactants, lubricants, fluidity promoters, colorants, fragrances and the like can be appropriately used.
- compositions in the context of the present invention includes not only those applied to humans but also those applied to animals other than humans.
- a preferable blood concentration can be about 20 to 200 ng / ml, and preferably about 50 to 100 ng / ml.
- the dosage of the pharmaceutical composition of the present invention varies depending on the preparation form, administration method, type of subject to be administered, age, body weight, medical condition, etc., and can be administered in an amount suitable for each of them. .
- the concentration can be 2 mg / day or more per kg of body weight.
- the amount of active ingredient can be 80 mg to 160 mg per day, for example, 120 mg or more per day per adult.
- Such daily doses can be administered to a subject in need of prophylaxis or treatment at once or in portions.
- STC1 improves fibrosis
- STC1 lowers mitochondrial membrane potential by up-regulating UCP2, thereby reducing peroxide mass (ROS).
- ROS peroxide mass
- STC1 induces uncoupled respiration and improves the energy efficiency in a disordered environment, thereby exerting a disorder mitigating action.
- cell fibrosis is improved.
- STC1 fibrosis inhibitory effect in pathological model mice A pulmonary fibrosis model using the antimitotic action of bleomycin (Bleo), an anticancer drug, was used as a pathological model mouse, and the effect of STC1 was examined.
- Human Recombinant (r) STC1 was manufactured by BioVender. Specifically, a human-derived STC1 gene added with a TAG structure was introduced into 293 cells, and rSTC1 was isolated using the TAG sequence.
- mice Female, 10 weeks old
- anesthetic 300 ⁇ g of ketamine hydrochloride + 160 ng of xylazine diluted in 100 ⁇ L of physiological saline.
- Anesthesia was performed. Thereafter, the neck was incised to expose the trachea, and a mantle of a 23G Surfflow needle was inserted into the trachea.
- each of the following drugs was administered into the mouse trachea of each group from a surfflow mantle.
- Saline control group 50 ⁇ L of bleomycin-containing physiological saline (bleomycin concentration 400 ng / mL)
- STC1 administration group STC1 500 ng + bleomycin-containing physiological saline 50 ⁇ L
- NAC administration group positive control: NAC 3 mg + bleomycin-containing physiological saline 50 ⁇ L
- Normal lung group 50 ⁇ L of physiological saline
- HE histopathological staining
- EM Elastica Masson staining
- HE staining represents the entire tissue.
- EM staining indicates the degree of fibrosis, and the darker color indicates that the elastic fibers are increased and the fibrosis of the lung is worsening.
- staining represents the quantity of a peroxide, and it dye
- panel A represents HE staining and panel B represents EM staining.
- Fibrosis was induced in the saline control group (FIGS. 3 and 4), but fibrosis was suppressed in the STC1 administration group (FIGS. 1 and 2) and the NAC administration group (FIG. 5). That is, STC1 administration into the respiratory tract suppressed the progression of pulmonary fibrosis in the bleomycin pulmonary fibrosis model, and was markedly effective with STC1 and improved with NAC.
- FIG. 7 also shows the results of 8OHDG staining.
- the saline control group panel G
- the STC1 administration group panel H
- NAC administration group panel I
- FIG. 6, panel C It was comparable. Therefore, it was suggested that STC1 suppresses peroxidative stress caused by bleomycin, like NAC.
Abstract
Description
〔1〕 STC1を有効成分として含有する線維症の予防、治療及び/又は進行抑制用医薬組成物;
〔2〕 線維症が、肺線維症である、上記〔1〕記載の医薬組成物
が提供される。
線維症の改善にも利用されることがある従来の薬剤と比較して、STC1は有利である。プレドニン、シクロスポリンA(cyclosporin-A)、FK506等は、免疫を強力に抑制するため、易感染性の原因となる。これに対し、STC1は、免疫系の抑制を起こさないことが報告されている(Transgenic Res (2010) 19:1017?1039)ことから、易感染性の問題がないと期待される。また、N-アセチルシステイン(N-acetylcystein;NAC)は静脈投与ができないという欠点があり、STC1はNACと比較してもその点で有利であると考えられる。
なお、本発明に関して線維症の「改善」は、予防及び治療(軽快、治癒を含む)を包含する意味で用いられる。
病態モデルマウスとして、抗ガン剤であるブレオマイシン(Bleo)の有糸分裂阻害作用を利用した肺線維症モデルを使用し、STC1の作用を調べた。
(2)STC1投与群: STC1 500ng+ブレオマイシン含有生理食塩水50μL
(3)NAC投与群(ポジティブコントロール): NAC 3mg+ブレオマイシン含有生理食塩水50μL
(4)正常肺群: 生理食塩水50μL
HE染色は組織の全体像を表す。EM染色は線維化の程度を表し、色が濃くなっているのは弾性線維が増えて肺の線維化が悪化していることを示す。また、8OHDG染色は過酸化物の量を表し、過酸化物が多いほど濃く染色される。
Claims (2)
- スタニオカルシン1(STC1)を有効成分として含有する線維症の予防、治療及び/又は進行抑制用医薬組成物。
- 線維症が、肺線維症である、請求項1記載の医薬組成物。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013523901A JP5946191B2 (ja) | 2011-07-09 | 2012-07-03 | 線維症予防又は治療用医薬組成物 |
EP12812138.1A EP2730288B1 (en) | 2011-07-09 | 2012-07-03 | Stanniocalcin 1 for preventing or treating pulmonary fibrosis |
US14/130,387 US9060988B2 (en) | 2011-07-09 | 2012-07-03 | Method for treating pulmonary fibrosis using a pharmaceutical composition containing stanniocalcin 1 (STC1) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011152392 | 2011-07-09 | ||
JP2011-152392 | 2011-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013008681A1 true WO2013008681A1 (ja) | 2013-01-17 |
Family
ID=47505973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2012/066971 WO2013008681A1 (ja) | 2011-07-09 | 2012-07-03 | 線維症予防又は治療用医薬組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9060988B2 (ja) |
EP (1) | EP2730288B1 (ja) |
JP (1) | JP5946191B2 (ja) |
WO (1) | WO2013008681A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022004054A1 (ja) * | 2020-06-30 | 2022-01-06 | 国立大学法人東北大学 | Stat3のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07188051A (ja) | 1993-11-16 | 1995-07-25 | Pola Chem Ind Inc | 骨代謝調節物質及び代謝性骨疾患治療薬 |
WO2000016795A1 (fr) | 1998-09-17 | 2000-03-30 | Snow Brand Milk Products Co., Ltd. | Agents pour la prevention et/ou le traitement de l'obesite |
JP2000229880A (ja) | 1999-02-10 | 2000-08-22 | Snow Brand Milk Prod Co Ltd | 骨形成促進剤 |
WO2002004013A1 (fr) | 2000-07-11 | 2002-01-17 | Bml, Inc. | Remedes pour maladies osseuses |
WO2010051347A1 (en) | 2008-10-31 | 2010-05-06 | David Sheikh-Hamad | A method for cardioprotection |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
-
2012
- 2012-07-03 WO PCT/JP2012/066971 patent/WO2013008681A1/ja active Application Filing
- 2012-07-03 EP EP12812138.1A patent/EP2730288B1/en active Active
- 2012-07-03 US US14/130,387 patent/US9060988B2/en active Active
- 2012-07-03 JP JP2013523901A patent/JP5946191B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07188051A (ja) | 1993-11-16 | 1995-07-25 | Pola Chem Ind Inc | 骨代謝調節物質及び代謝性骨疾患治療薬 |
WO2000016795A1 (fr) | 1998-09-17 | 2000-03-30 | Snow Brand Milk Products Co., Ltd. | Agents pour la prevention et/ou le traitement de l'obesite |
JP2000229880A (ja) | 1999-02-10 | 2000-08-22 | Snow Brand Milk Prod Co Ltd | 骨形成促進剤 |
WO2002004013A1 (fr) | 2000-07-11 | 2002-01-17 | Bml, Inc. | Remedes pour maladies osseuses |
WO2010051347A1 (en) | 2008-10-31 | 2010-05-06 | David Sheikh-Hamad | A method for cardioprotection |
Non-Patent Citations (10)
Title |
---|
AJRCCM, no. 162, 2000, pages 225 - 231 |
AKI MATSUMOTO: "Toppatsusei Haisen'isho", JAPANESE JOURNAL OF CLINICAL MEDICINE 0047-1852, vol. 64, no. 7, 2006, pages 1354 - 1360, XP008172862 * |
CANCER RES., vol. 68, no. 13, 2008, pages 5198 - 5205 |
CANCER RES., vol. 69, no. 6, 2009, pages 2163 - 2166 |
HUANG, L. ET AL.: "Anti-inflammatory and renal protective actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis", AM J PATHOL, vol. 174, no. 4, 2009, pages 1368 - 78, XP055140487 * |
JOURNAL OF LEUKOCYTE BIOLOGY, vol. 86, 2009, pages 981 - 988 |
PNAS, vol. 14, 2003, pages 8407 - 8411 |
THE AMERICAN JOURNAL OF PATHOLOGY, vol. 174, no. 4, 2009, pages 1368 - 1378 |
TOHOKU UNIVERSITY GLOBAL COE NETWORK MEDICINE WINTER CAMP OF GCOE 2010, February 2011 (2011-02-01) |
TRANSGENIC RES., vol. 19, 2010, pages 1017 - 1039 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022004054A1 (ja) * | 2020-06-30 | 2022-01-06 | 国立大学法人東北大学 | Stat3のリン酸化抑制剤、自己免疫疾患及びコロナウイルス感染症の予防又は治療剤 |
Also Published As
Publication number | Publication date |
---|---|
US9060988B2 (en) | 2015-06-23 |
JP5946191B2 (ja) | 2016-07-05 |
JPWO2013008681A1 (ja) | 2015-02-23 |
US20140135266A1 (en) | 2014-05-15 |
EP2730288A4 (en) | 2015-03-25 |
EP2730288B1 (en) | 2017-09-06 |
EP2730288A1 (en) | 2014-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8637458B2 (en) | Insulin with a stable basal release profile | |
US10987338B2 (en) | Composition containing artesunate | |
EP4292651A2 (en) | Liponucleotide-based therapy for ards | |
US20210069098A1 (en) | Ribavirin perflubron emulsion composition for treating viral diseases | |
JP2022019937A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物 | |
JP5946191B2 (ja) | 線維症予防又は治療用医薬組成物 | |
US10342852B2 (en) | Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein | |
JP5792322B2 (ja) | ビタミンdおよびメトホルミン含有医薬組成物 | |
CN112294787B (zh) | 一种治疗肝癌的联合用药物 | |
US20180353539A1 (en) | Metal complexes as pharmaceuticals for treatment and prevention of cancer and inflammatory diseases | |
EP3354268A1 (en) | Tumor prevention and treatment drug and applications thereof | |
US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
CN115813920B (zh) | 1,2,4三唑并4,3-b哒嗪衍生物在制备治疗慢性肾病的药物中的应用 | |
EP4189402A2 (en) | Method and composition of upregulating rna interference process | |
CN108310369B (zh) | 一种用于经皮冠状动脉介入治疗的给药系统 | |
WO2012144619A1 (ja) | 経口投与用慢性肝疾患治療剤 | |
Meissner | Antiviral drugs for prophylaxis and treatment of influenza | |
WO2006095433A1 (ja) | ウシの消化器疾患治療剤 | |
JP2021161105A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物 | |
CN117797155A (zh) | 对抗氯胺酮毒性的药物制剂 | |
JP2012219065A (ja) | ケトーシス又はケトアシドーシス予防又は治療剤 | |
EP3820462A1 (en) | Compositions for the treatment of copper deficiency and methods of use | |
WO2020160813A1 (en) | Method of treatment and pharmaceutical dosage form | |
WO2019104429A1 (en) | Methods for regulating endogenous production of checkpoint molecule antagonists | |
CN110025606A (zh) | 吉非罗齐的新用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12812138 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2013523901 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14130387 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2012812138 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012812138 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |